Menu
Search
|

Menu

Close
X

Acasti Pharma Inc ACST.OQ (NASDAQ Stock Exchange Capital Market)

0.97 USD
-0.02 (-1.73%)
As of Feb 23
chart
Previous Close 0.99
Open 0.99
Volume 41,851
3m Avg Volume 134,025
Today’s High 1.00
Today’s Low 0.96
52 Week High 3.34
52 Week Low 0.85
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
--
8.35
Price to Book (MRQ)
vs sector
--
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
--
15.84
LT Debt to Equity (MRQ)
vs sector
--
12.39
Return on Investment (TTM)
vs sector
--
13.63
Return on Equity (TTM)
vs sector
--
15.39

EXECUTIVE LEADERSHIP

Roderick Carter
Executive Chairman of the Board, Since 2016
Salary: --
Bonus: --
Janelle D'Alvise
President, Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Linda O'Keefe
Chief Financial Officer, Since 2016
Salary: --
Bonus: --
Pierre Lemieux
Chief Operating Officer, Since 2010
Salary: $184,115.00
Bonus: --
Laurent Harvey
Vice President- Clinical and Non-Clinical Affairs, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

545 Prom du Centropolis Suite 10
LAVAL   QC   H7T 0A3

Phone: +1450.6872262

Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG). The Company's drug candidate is CaPre, an OM3 phospholipid, which is being developed for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream (over 500 mg/dL) (severe hypertriglyceridemia or severe HTG).

SPONSORED STORIES